Tafluprost, a Prostaglandin F2α Analog, Has Therapeutic Potential for Androgenic Alopecia through Modulation of Hair Cycle

Topical tacrolimus is being considered for androgenetic alopecia, though its effectiveness is unproven. Other treatments mentioned include minoxidil, dutasteride, cyclosporine, and teicoplanin, with discussions on blocking the prolactin receptor for hair growth.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.

The user is using oral finasteride, topical minoxidil, and tretinoin to treat hair loss. After two months, there is noticeable thickening and maintenance of the hairline.

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

A 27-year-old woman with advanced female pattern hair loss and telogen effluvium is experiencing increased hair shedding after starting oral minoxidil and finasteride. She is seeking advice and reassurance from others who have experienced similar issues, while also considering additional treatments like dermapen and ensuring her nutritional needs are met.